Grafa News and Videos — Page 246

Rio Tinto (ASX:RIO) plans to expand its marketing operations to trade third-party metals and utilise financial derivatives.

Bathla Group will close its operations and stand down its remaining workforce after short-term emergency funding expired.

FingerMotion (NASDAQ:FNGR) announced that it has received indications of interest representing approximately 52.5 MW of potential demand for its Alberta power-and-compute program.

Oracle (NYSE:ORCL) shares declined on Thursday following reports that the company has taken steps to reduce its financial exposure to a major artificial intelligence data center project in New Mexico.

Upbound Group (NASDAQ:UPBD) announced that its Board of Directors has approved a quarterly cash dividend of $0.39 per common share for the fourth quarter of 2026.

Mesoblast (NASDAQ:MESO) announced that the U.S. Food and Drug Administration (FDA) has approved the use of a new potency testing method for commercial batches of Ryoncil.

Satellos Bioscience (NASDAQ:MSLE) announced that it has received U.S. Food and Drug Administration (FDA) clearance to begin studying forazapadin in patients with facioscapulohumeral muscular dystrophy (FSHD).

Ligand Pharmaceuticals (NASDAQ:LGND) announced a financing agreement with AvenCell Therapeutics that could provide up to $47 million to support development of AvenCell’s cancer treatment pipeline.

IMUNON (NASDAQ:IMNN) presented Phase 2 survival results and Phase 3 enrollment updates for IMNN-001, its investigational therapy for advanced ovarian cancer.

Ainos (NASDAQ:AIMD) announced that it has entered into a VELDONA license agreement with BioPhoenix, establishing a conditional collaboration framework with a potential value of up to $10 million.